These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11202538)

  • 1. Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program.
    Weiner S; Dischler J; Horvitz C
    Am J Health Syst Pharm; 2001 Jan; 58(2):146-50. PubMed ID: 11202538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing an on-site pharmacy in a community health center to help indigent patients access medications and to improve care.
    Dent LA; Stratton TP; Cochran GA
    J Am Pharm Assoc (Wash); 2002; 42(3):497-507. PubMed ID: 12030637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical manufacturer assistance programs for indigent patients: solution or symptom?
    Van Diepen LR
    Am J Health Syst Pharm; 2001 Jan; 58(2):162-3. PubMed ID: 11202541
    [No Abstract]   [Full Text] [Related]  

  • 4. Program for procurement of drugs for indigent patients.
    Decane BE; Chapman J
    Am J Hosp Pharm; 1994 Mar; 51(5):669-71. PubMed ID: 8203387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical manufacturer assistance programs.
    Chisholm MA; DiPiro JT
    Arch Intern Med; 2002 Apr; 162(7):780-4. PubMed ID: 11926851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients.
    Gao L; Joseph J; Santoro-Levy M; Multz AS; Gotlieb VK
    Hosp Pharm; 2016 Jul; 51(7):572-6. PubMed ID: 27559190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who benefits from drug discounts? Drugmakers, hospitals battle over indigent-care program.
    Lee J
    Mod Healthc; 2013 Jul; 43(28):8-9. PubMed ID: 24044228
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center.
    Farano JL; Kandah HM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):765-769. PubMed ID: 31232209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a patient medication assistance program in a community pharmacy setting.
    Mounts VL; Ringenberg DG; Rhees K; Partridge C
    J Am Pharm Assoc (2003); 2005; 45(1):76-81. PubMed ID: 15730120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs to physician offices of providing medications to medically indigent patients via pharmaceutical manufacturer prescription assistance programs.
    Clay P; Vaught E; Glaros A; Mangum S; Hansen D; Lindsey C
    J Manag Care Pharm; 2007; 13(6):506-14. PubMed ID: 17672812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a Prescription-Assistance Program for Medically Uninsured Patients With Cancer: Case Study of a Public Hospital Experience in New York State.
    Gao L; Joseph J; Santoro-Levy M; Gotlieb VK; Multz AS
    J Oncol Pract; 2014 Mar; 10(2):104. PubMed ID: 29452556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication assistance programs for uninsured and indigent patients.
    Chisholm MA; Reinhardt BO; Vollenweider LJ; Kendrick BD; DiPiro JT
    Am J Health Syst Pharm; 2000 Jun; 57(12):1131-6. PubMed ID: 10911511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of a comprehensive pharmaceutical care program for an underserved population.
    Mascardo LA; Spading KA; Abramowitz PW
    Am J Health Syst Pharm; 2012 Jul; 69(14):1225-30. PubMed ID: 22761077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient assistance programs and patient advocacy foundations: alternatives for obtaining prescription medications when insurance fails.
    Johnson PE
    Am J Health Syst Pharm; 2006 Nov; 63(21 Suppl 7):S13-7. PubMed ID: 17057055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit analysis of a clinical pharmacist-managed medication assistance program in a renal transplant clinic.
    Chisholm MA; Vollenweider LJ; Mulloy LL; Wynn JJ; Wade WE; DiPiro JT
    Clin Transplant; 2000 Aug; 14(4 Pt 1):304-7. PubMed ID: 10945200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Built for the road ahead.
    Mansour A
    Healthc Financ Manage; 2015 Oct; 69(10):76-81. PubMed ID: 26595980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacist-facilitated enrollment in medication assistance programs in a private ambulatory care clinic.
    Sarrafizadeh M; Waite NM; Hobson EH; Migden H
    Am J Health Syst Pharm; 2004 Sep; 61(17):1816-20. PubMed ID: 15462253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computer-guided academic detailing as part of a drug benefit program.
    Keys PW; Goetz CM; Keys PA; Sterchele JA; Snedden TM; Livengood BH
    Am J Health Syst Pharm; 1995 Oct; 52(20):2199-203; discussion 22034. PubMed ID: 8564590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding clinical and information services to the ambulatory older adult through community outreach programs.
    Evans P; Aungst TD; Massey C; Bartlett D
    Consult Pharm; 2015 Jan; 30(1):31-7. PubMed ID: 25591029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personal Responsibility and Work Opportunity Reconciliation Act of 1996 (PRWORA); interpretation of "federal public benefit"--HHS. Notice with comment period.
    Fed Regist; 1998 Aug; 63(149):41658-61. PubMed ID: 10181721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.